Tags

Type your tag names separated by a space and hit enter

Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
J Bone Miner Res. 2010 Nov; 25(11):2297-303.JB

Abstract

Anabolic treatment with teriparatide of postmenopausal osteoporotic patients previously treated with bisphosphonates is a new therapeutic approach. However, its effects on the bone mineralization density distribution (BMDD) are unknown. We studied paired transiliac bone biopsy samples taken before and after 1 year of treatment with recombinant human parathyroid hormone peptide 1-34 (teriparatide) from 16 osteoporotic women treated with either alendronate (priorALN) or risedronate (priorRIS) for at least 2 years and subsequently treated for 12 months with teriparatide. Cancellous (Cn.) and cortical (Ct.) BMDD values were measured using quantitative backscattered electron imaging. At baseline, BMDD values of priorALN and priorRIS women were similar and within the normal range. One year of teriparatide treatment caused significant effects on the BMDD. Analyzing changes from baseline for each bisphosphonate group separately, priorALN patients revealed increases in the portion of low mineralized bone areas (Cn.Ca(Low) +25.9%, Ct.Ca(Low) +62.0%, both p < .05) and Ct. heterogeneity of mineralization (Ct.Ca(Width) +22.8%, p < .001). PriorRIS patients showed increased mineralization heterogeneity (Cn.Ca(Width) +14.8%, p < .05, and Ct.Ca(Width) +15.8%, p < .001). Analysis of the influence of the prior bisphosphonate treatment showed that the BMDD response to 1 year of teriparatide treatment did not depend on the type of prior bisphosphonate. In consequence, priorALN and priorRIS groups were combined. The pooled groups revealed increased Cn.Ca(Width) and Ct.Ca(Width) (+10.7%, p < .01, and +19.6%, p < .001, respectively) as well as increased Cn.Ca(Low) and Ct.Ca(Low) (+18.2%, p < .05, and +36.6%, p < .01, respectively). In summary, our findings indicate a significant effect of teriparatide on BMDD when administered subsequent to a bisphosphonate in agreement with teriparatide's anabolic action.

Authors+Show Affiliations

Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4th Medical Department, Hanusch Hospital, Vienna, Austria. barbara.misof@osteologie.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20683883

Citation

Misof, Barbara M., et al. "Effects of 1 Year of Daily Teriparatide Treatment On Iliacal Bone Mineralization Density Distribution (BMDD) in Postmenopausal Osteoporotic Women Previously Treated With Alendronate or Risedronate." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, vol. 25, no. 11, 2010, pp. 2297-303.
Misof BM, Paschalis EP, Blouin S, et al. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res. 2010;25(11):2297-303.
Misof, B. M., Paschalis, E. P., Blouin, S., Fratzl-Zelman, N., Klaushofer, K., & Roschger, P. (2010). Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 25(11), 2297-303. https://doi.org/10.1002/jbmr.198
Misof BM, et al. Effects of 1 Year of Daily Teriparatide Treatment On Iliacal Bone Mineralization Density Distribution (BMDD) in Postmenopausal Osteoporotic Women Previously Treated With Alendronate or Risedronate. J Bone Miner Res. 2010;25(11):2297-303. PubMed PMID: 20683883.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. AU - Misof,Barbara M, AU - Paschalis,Eleftherios P, AU - Blouin,Stéphane, AU - Fratzl-Zelman,Nadja, AU - Klaushofer,Klaus, AU - Roschger,Paul, PY - 2010/8/5/entrez PY - 2010/8/5/pubmed PY - 2011/2/10/medline SP - 2297 EP - 303 JF - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JO - J Bone Miner Res VL - 25 IS - 11 N2 - Anabolic treatment with teriparatide of postmenopausal osteoporotic patients previously treated with bisphosphonates is a new therapeutic approach. However, its effects on the bone mineralization density distribution (BMDD) are unknown. We studied paired transiliac bone biopsy samples taken before and after 1 year of treatment with recombinant human parathyroid hormone peptide 1-34 (teriparatide) from 16 osteoporotic women treated with either alendronate (priorALN) or risedronate (priorRIS) for at least 2 years and subsequently treated for 12 months with teriparatide. Cancellous (Cn.) and cortical (Ct.) BMDD values were measured using quantitative backscattered electron imaging. At baseline, BMDD values of priorALN and priorRIS women were similar and within the normal range. One year of teriparatide treatment caused significant effects on the BMDD. Analyzing changes from baseline for each bisphosphonate group separately, priorALN patients revealed increases in the portion of low mineralized bone areas (Cn.Ca(Low) +25.9%, Ct.Ca(Low) +62.0%, both p < .05) and Ct. heterogeneity of mineralization (Ct.Ca(Width) +22.8%, p < .001). PriorRIS patients showed increased mineralization heterogeneity (Cn.Ca(Width) +14.8%, p < .05, and Ct.Ca(Width) +15.8%, p < .001). Analysis of the influence of the prior bisphosphonate treatment showed that the BMDD response to 1 year of teriparatide treatment did not depend on the type of prior bisphosphonate. In consequence, priorALN and priorRIS groups were combined. The pooled groups revealed increased Cn.Ca(Width) and Ct.Ca(Width) (+10.7%, p < .01, and +19.6%, p < .001, respectively) as well as increased Cn.Ca(Low) and Ct.Ca(Low) (+18.2%, p < .05, and +36.6%, p < .01, respectively). In summary, our findings indicate a significant effect of teriparatide on BMDD when administered subsequent to a bisphosphonate in agreement with teriparatide's anabolic action. SN - 1523-4681 UR - https://www.unboundmedicine.com/medline/citation/20683883/Effects_of_1_year_of_daily_teriparatide_treatment_on_iliacal_bone_mineralization_density_distribution__BMDD__in_postmenopausal_osteoporotic_women_previously_treated_with_alendronate_or_risedronate_ L2 - https://doi.org/10.1002/jbmr.198 DB - PRIME DP - Unbound Medicine ER -